PURPOSE: Currently, no validated blood-based assays accurately predict treatment response or outcome in melanoma patients. We hypothesized that methylation of tumor-related genes detected in serum DNA could predict disease outcome and therapeutic response in patients receiving concurrent biochemotherapy (BC) for metastatic melanoma. PATIENTS AND METHODS: American Joint Committee on Cancer stage IV melanoma patients (N = 50) had blood drawn before administration of BC. Patients (n = 47) were classified as BC responders or nonresponders. Responders (n = 23) demonstrated a complete or partial response following BC; nonresponders (n = 24) demonstrated progressive disease. Hypermethylation of Ras association domain family 1 (RASSF1A), retinoic acid receptor-beta2 (RAR-beta2), and O6-methylguanine DNA methyltransferase (MGMT) genes were assessed by methylation-specific polymerase chain reaction. RESULTS: Circulating methylated RASSF1A was significantly less frequent for responders (three of 23 patients; 13%) than nonresponders (10 of 24 patients; 42%; P = .028). Patients with RASSF1A, RAR-beta2, or at least one serum methylated gene had significantly worse overall survival than patients with no methylated genes (log-rank, P = .013, .021, and .01, respectively). Methylated RASSF1A was the only factor that significantly correlated with overall survival and BC response (risk ratio, 2.38; 95% CI, 1.16 to 4.86; P = .018; odds ratio = 0.21; 95% CI, 0.05 to 0.90; P = .036). CONCLUSION: Detection of circulating methylated DNA in serum can predict response to BC and disease outcome.
PURPOSE: Currently, no validated blood-based assays accurately predict treatment response or outcome in melanomapatients. We hypothesized that methylation of tumor-related genes detected in serum DNA could predict disease outcome and therapeutic response in patients receiving concurrent biochemotherapy (BC) for metastatic melanoma. PATIENTS AND METHODS: American Joint Committee on Cancer stage IV melanomapatients (N = 50) had blood drawn before administration of BC. Patients (n = 47) were classified as BC responders or nonresponders. Responders (n = 23) demonstrated a complete or partial response following BC; nonresponders (n = 24) demonstrated progressive disease. Hypermethylation of Ras association domain family 1 (RASSF1A), retinoic acid receptor-beta2 (RAR-beta2), and O6-methylguanine DNA methyltransferase (MGMT) genes were assessed by methylation-specific polymerase chain reaction. RESULTS: Circulating methylated RASSF1A was significantly less frequent for responders (three of 23 patients; 13%) than nonresponders (10 of 24 patients; 42%; P = .028). Patients with RASSF1A, RAR-beta2, or at least one serum methylated gene had significantly worse overall survival than patients with no methylated genes (log-rank, P = .013, .021, and .01, respectively). Methylated RASSF1A was the only factor that significantly correlated with overall survival and BC response (risk ratio, 2.38; 95% CI, 1.16 to 4.86; P = .018; odds ratio = 0.21; 95% CI, 0.05 to 0.90; P = .036). CONCLUSION: Detection of circulating methylated DNA in serum can predict response to BC and disease outcome.
Authors: J F Costello; M C Frühwald; D J Smiraglia; L J Rush; G P Robertson; X Gao; F A Wright; J D Feramisco; P Peltomäki; J C Lang; D E Schuller; L Yu; C D Bloomfield; M A Caligiuri; A Yates; R Nishikawa; H Su Huang; N J Petrelli; X Zhang; M S O'Dorisio; W A Held; W K Cavenee; C Plass Journal: Nat Genet Date: 2000-02 Impact factor: 38.330
Authors: Naoyuki Umetani; Michiel F G de Maat; Takuji Mori; Hiroya Takeuchi; Dave S B Hoon Journal: Biochem Biophys Res Commun Date: 2005-04-01 Impact factor: 3.575
Authors: Heidi Fiegl; Simone Millinger; Elisabeth Mueller-Holzner; Christian Marth; Christian Ensinger; Andreas Berger; Helmut Klocker; Georg Goebel; Martin Widschwendter Journal: Cancer Res Date: 2005-02-15 Impact factor: 12.701
Authors: Masaru Shinozaki; Dave S B Hoon; Armando E Giuliano; Nora M Hansen; He-Jing Wang; Roderick Turner; Bret Taback Journal: Clin Cancer Res Date: 2005-03-15 Impact factor: 12.531
Authors: S J O'Day; G Gammon; P D Boasberg; M A Martin; T S Kristedja; M Guo; S Stern; S Edwards; P Fournier; M Weisberg; M Cannon; N W Fawzy; T D Johnson; R Essner; L J Foshag; D L Morton Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Anne Marie Asemissen; Carmen Scheibenbogen; Anne Letsch; Kristoffer Hellstrand; Fredrik Thorén; Kurt Gehlsen; Alexander Schmittel; Eckhard Thiel; Ulrich Keilholz Journal: Clin Cancer Res Date: 2005-01-01 Impact factor: 12.531
Authors: Carmen Jerónimo; Rui Henrique; Mohammad O Hoque; Elizabeth Mambo; Franclim R Ribeiro; Graça Varzim; Jorge Oliveira; Manuel R Teixeira; Carlos Lopes; David Sidransky Journal: Clin Cancer Res Date: 2004-12-15 Impact factor: 12.531
Authors: Takuji Mori; Steve R Martinez; Steven J O'Day; Donald L Morton; Naoyuki Umetani; Minoru Kitago; Atsushi Tanemura; Sandy L Nguyen; Andy N Tran; He-Jing Wang; Dave S B Hoon Journal: Cancer Res Date: 2006-07-01 Impact factor: 12.701
Authors: Melody J Xu; Jay F Dorsey; Ravi Amaravadi; Giorgos Karakousis; Charles B Simone; Xiaowei Xu; Wei Xu; Erica L Carpenter; Lynn Schuchter; Gary D Kao Journal: Oncologist Date: 2015-11-27